·
- Patients taking treatment with melphalan are advised to report any signs/symptoms of thrombocytopenia, leukopenia, and anemia. Patients are informed of the need for the routine blood counts.
- Patients taking treatment with melphalan 50 mg are apprised to report symptoms of vomiting, nausea, and diarrhea, so that appropriate antiemetic or antidiarrheal drugs can be used.
- Patients taking melphalan are advised to promptly report symptoms of hypersensitivity reactions including changes involving the skin, breathing or heart rate, so that corticosteroid or antihistamine therapy can be used.
- Females of reproductive potential are apprised to avoid pregnancy, which may include use of apt contraception while on and following treatment with melphalan. Females are advised to contact your doctor if you become pregnant, or in case pregnancy is suspected, while on melphalan.
- Women taking this medication are apprised that breastfeeding should be interrupted during treatment, as it may be hazardous to the baby.
- Males with female sexual partners of reproductive potential are advised that you must use apt contraception while on and following treatment with melphalan.
- Patients taking treatment with melphalan are advised that your blood should be tested prior to and during the treatment.
